Piramal Pharma Limited announced its unaudited standalone financial results for the quarter and half-year ended September 30, 2025. The company’s total income for the quarter stood at ₹1,329.23 crore, with a profit before tax of ₹247.41 crore. The results, reviewed by the Audit Committee and approved by the Board of Directors, reflect the company’s performance in the pharmaceutical sector.
Financial Performance
Piramal Pharma Limited has released its unaudited standalone financial results for Q2 2026 (July-September) and the half-year ended September 30, 2025. Key financial highlights include:
Key Financials
Total Income for Q2 2026: ₹1,329.23 crore compared to ₹1,390.77 crore for the same quarter last year.
Profit before tax for Q2 2026: ₹247.41 crore compared to ₹275.71 crore for the same quarter last year.
Net Profit after tax for Q2 2026: ₹196.33 crore compared to ₹210.06 crore for the same quarter last year.
Balance Sheet Highlights
Total Non-Current Assets: ₹7,117.57 crore
Total Current Assets: ₹3,736.55 crore
Equity: ₹7,742.74 crore
Consolidated Financial Results
Piramal Pharma Limited also announced its unaudited consolidated financial results for Q2 2026.
Total Income: ₹2,109.32 crore Loss before Share of profit of associates: ₹(60.97) crore Net Loss after Tax: ₹(99.22) crore The results have been reviewed by the Audit Committee and approved by the Board of Directors. A claim amount of ₹20.74 crores received was shown as an exceptional item. Source: BSEOther Considerations
